Track Magenta Therapeutics's total liabilities ($46M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), MGTA shows a total liabilities of $46M. That compares with $20M in the prior-year period — up 128.1% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, MGTA's total liabilities is now $46M (was $20M) — a 128.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Magenta Therapeutics is outperforming or lagging.
Tracking MGTA's total liabilities over time shows whether Magenta Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $46M That compares with $20M in the prior-year period — up 128.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total liabilities page, Stockcircle has Magenta Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $46M) with ownership activity and broader fundamentals.
Magenta Therapeutics's total liabilities is $46M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.